

## **MEANS AND STANDARD DEVIATIONS FOR MEASURES INCLUDED IN THE 2013 QUALITY AND RESOURCE USE REPORTS**

---

### **TABLES**

---

Table 1. CMS-Calculated Outcome Measures. 2013 Performance Means and Standard Deviations for All TINs Receiving a 2013 QRUR. ....	2
Table 2. Administrative Claims-Based Quality Measures. 2013 Performance Means and Standard Deviations for All TINs Electing this Reporting Option in 2013. ....	3
Table 3. GPRO Web Interface Quality Measures. 2013 Performance Means and Standard Deviations for All TINs Electing this Reporting Option in 2013. ....	5
Table 4. GPRO Registry Quality Measures. 2013 Performance Means and Standard Deviations for All TINs Electing this Reporting Option in 2013. ....	7
Table 5. Payment-Standardized and Risk-Adjusted Per Capita Costs for All Beneficiaries and for Beneficiaries with Specific Conditions. 2013 Performance Means and Standard Deviations for TINs Receiving a 2013 QRUR, by TIN Size. ....	20
Table 6. Performance on Payment-Standardized, Risk-Adjusted and Specialty-Adjusted Cost Measures for the 2016 Value-Based Payment Modifier. 2013 Performance Means and Standard Deviations for TINs Receiving a 2013 QRUR, by TIN Size. ....	21
Table 7. 2013 Aggregate Group-Level Performance on PQRS Quality Measures for the 2016 Value-Based Payment Modifier. 2013 Performance Means and Standard Deviations for TINs Receiving a 2013 QRUR, Among Incentive-Eligible Individual Eligible Professionals. ....	22
Table 8. 2013 Composite Score Means and Standard Deviations Used for the 2013 QRUR and 2015 Value-Based Payment Modifier. ....	39

### **ACRONYMS**

---

QRUR = Quality and Resource Use Report; TIN = Taxpayer Identification Number; PQRS = Physician Quality Reporting System; GPRO = Group Practice Reporting Option; CMS = Centers for Medicare & Medicaid Service

## **MEANS AND STANDARD DEVIATIONS FOR MEASURES INCLUDED IN THE 2013 QUALITY AND RESOURCE USE REPORT**

---

### **OVERVIEW**

The 2013 Quality and Resource Use Report (QRUR) shows how physicians in solo practices and groups, identified by their Taxpayer Identification Numbers (TINs), performed in 2013 on quality and cost measures that will be used to calculate value-based performance in 2015 (QRUR Exhibits 5 and 8). In addition, the 2013 QRUR provides information about 2013 performance on new measures that will apply to the calculation of value-based performance in 2016 (for which the period of performance will be calendar year 2014). These latter exhibits (QRUR Exhibits 13 and 14) are included for informational purposes only and will not affect Medicare Physician Fee Schedule reimbursements in 2015.

This document provides additional information about (1) the number of TINs reporting a quality or cost measure in 2013, (2) the peer group mean performance rate for each measure in 2013, and (3) the standard deviation in peer group performance rates for each measure in 2013. Tables 1-4 in this document refer to the quality measures reported in QRUR Exhibit 5; Table 5 refers to the cost measures reported in QRUR Exhibit 8; and Tables 6 and 7 refer to the new measures reported in QRUR Exhibits 13 and 14.

Please note that the measure means and standard deviations presented in this document, based on 2013 performance, may differ from those shown in the relevant QRUR exhibits. This is because the QRURs report the benchmarks used to calculate value-based performance: for each quality measure, this is the case-weighted mean performance rate for the year prior to the performance year (2012, rather than 2013). In addition, the data that will be reported in the 2014 QRURs will differ slightly from the 2013 means and standard deviations presented in this document because of the application of case-weighting and changes to the cohort of TINs included in the peer group calculations.

**Table 1. CMS-Calculated Outcome Measures. 2013 Performance Means and Standard Deviations for All TINs Receiving a 2013 QRUR.**

CMS calculates performance on three quality outcome measures for all TINs receiving a 2013 QRUR, regardless of which PQRS reporting mechanism they use. For TINs that did not report any PQRS quality measures in 2013, QRUR Exhibit 5 will show only these CMS-calculated quality outcome measures.

			TINs with One or More Physicians		
PQRS Measure Number and Name		Quality Domain	Number of TINs Reporting	Mean	Standard Deviation
CMS-1**	Acute Conditions Composite	Care Coordination	143,398	5.55	33.66
-	PQI-11 Bacterial Pneumonia**	Care Coordination	143,398	8.11	63.92
-	PQI-12 Urinary Tract Infection**	Care Coordination	143,398	5.31	44.82
-	PQI-10 Dehydration**	Care Coordination	143,398	3.20	57.21
CMS-2**	Chronic Conditions Composite	Care Coordination	114,015	42.19	157.80
-	Diabetes (composite of 4 indicators)**	Care Coordination	106,338	18.25	140.82
-	PQI-5 Chronic Obstructive Pulmonary Disease (COPD) or Asthma**	Care Coordination	83,812	71.56	286.95
-	PQI-8 Heart Failure**	Care Coordination	88,157	89.01	321.49
CMS-3**	All-Cause Hospital Readmissions	Care Coordination	82,593	15.84	0.57

Note: CMS-1, CMS-2, and CMS-3 are calculated by CMS using administrative claims data.

\*\*Lower performance rates on this measure indicate better performance.

**Table 2. Administrative Claims-Based Quality Measures. 2013 Performance Means and Standard Deviations for All TINs Electing this Reporting Option in 2013.**

In 2013, registered Group Practice Reporting Option (GPRO) TINs could elect to have CMS calculate performance on a set of quality measures derived from Medicare fee-for-service claims (the administrative claims reporting option). CMS also used this mechanism to calculate quality performance for TINs with 100 or more eligible professionals (at least one of whom is a physician) who registered, selected the GPRO web interface or registry as a reporting mechanism, elected quality tiering, and reported at least one PQRS measure in 2013, but who failed to meet the criteria for satisfactory reporting. Please note, however, that the administrative claims reporting option will not be available in 2014.

Measure Name	Quality Domain	TINs with One or More Physicians		
		Number of TINs Reporting	Mean	Standard Deviation
- Osteoporosis Management in Women $\geq$ 67 Who Had a Fracture	Clinical Process/Effectiveness	778	15.57	11.54
- Use of Spirometry Testing to Diagnose Chronic Obstructive Pulmonary Disease (COPD)	Clinical Process/Effectiveness	830	34.53	15.70
- Dilated Eye Exam for Beneficiaries $\leq$ 75 with Diabetes	Clinical Process/Effectiveness	874	52.55	16.08
- Hba1c Testing for Beneficiaries $\leq$ 75 with Diabetes	Clinical Process/Effectiveness	874	80.25	19.74
- Nephropathy Screening Test or Evidence of Existing Nephropathy for Beneficiaries $\leq$ 75 with Diabetes	Clinical Process/Effectiveness	874	85.82	13.15
- Lipid Profile for Beneficiaries $\leq$ 75 with Diabetes	Clinical Process/Effectiveness	874	74.31	20.43
- Lipid Profile for Beneficiaries with Ischemic Vascular Disease (IVD)	Clinical Process/Effectiveness	856	70.74	18.43
- Adherence to Statin Therapy for Beneficiaries with Coronary Artery Disease (CAD)	Clinical Process/Effectiveness	787	69.60	16.53
- Antidepressant Treatment for Depression:	Clinical Process/Effectiveness	-	-	-
- Acute Phase Treatment (at least 12 weeks)	Clinical Process/Effectiveness	813	59.50	17.76
- 1. Continuation Phase Treatment (at least 6 months)	Clinical Process/Effectiveness	813	41.03	16.41
- 2. Lipid Profile for Beneficiaries Who Started Lipid-Lowering Medications	Clinical Process/Effectiveness	864	35.79	13.77
- Breast Cancer Screening for Women Ages 50–74	Clinical Process/Effectiveness	879	62.48	16.76

Measure Name	Quality Domain	TINs with One or More Physicians		
		Number of TINs Reporting	Mean	Standard Deviation
- Use of High Risk Medications in the Elderly	Patient Safety	-	-	-
- 1. Patients Who Receive At Least One Drug to Be Avoided**	Patient Safety	872	19.67	9.49
- 2. Patients Who Receive At Least Two Different Drugs to Be Avoided**	Patient Safety	872	4.44	4.70
- Lack of Monthly International Normalized Ratio (INR) Monitoring for Beneficiaries on Warfarin**	Patient Safety	822	35.06	16.40
- Follow-Up After Hospitalization for Mental Illness	Care Coordination	-	-	-
- 1. Percentage of Patients Receiving Follow-Up Within 30 Days	Care Coordination	787	53.32	20.94
- 2. Percentage of Patients Receiving Follow-Up Within 7 Days	Care Coordination	787	28.34	17.95

Note: Administrative claims-based quality measures, unlike their PQRS counterparts, do not have measure numbers.

\*\*Lower performance rates on this measure indicate better performance.

**Table 3. GPRO Web Interface Quality Measures. 2013 Performance Means and Standard Deviations for All TINs Electing this Reporting Option in 2013.**

PQRS Measure Number and Name	Quality Domain	TINs with 25 or More Eligible Professionals (at least One of Whom is a Physician)			
		Number of TINs Reporting	Mean	Standard Deviation	
-	Coronary Artery Disease (CAD): Composite (All or Nothing Scoring)	Clinical Process/Effectiveness	137	74.26	13.71
CAD-2	Coronary Artery Disease (CAD): Lipid Control	Clinical Process/Effectiveness	136	81.63	13.21
CAD-7	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy—Diabetes or Left Ventricular Systolic Dysfunction (LVSD) (LVEF < 40%)	Clinical Process/Effectiveness	134	78.59	15.18
DM-2**	Diabetes Mellitus (DM): Hemoglobin A1c Poor Control	Clinical Process/Effectiveness	140	20.29	17.67
-	Diabetes Mellitus (DM) Composite (All or Nothing Scoring)	Clinical Process/Effectiveness	140	26.98	12.31
DM-13	Diabetes Mellitus (DM): High Blood Pressure Control	Clinical Process/Effectiveness	140	70.05	13.47
DM-14	Diabetes Mellitus (DM): Low Density Lipoprotein (LDL-C) Control	Clinical Process/Effectiveness	140	56.63	16.22
DM-15	Diabetes Mellitus (DM): Hemoglobin A1c Control (< 8%)	Clinical Process/Effectiveness	140	69.99	17.59
DM-16	Diabetes Mellitus (DM): Daily Aspirin or Antiplatelet Medication Use for Patients with Diabetes and Ischemic Vascular Disease (IVD)	Clinical Process/Effectiveness	136	84.58	17.01
DM-17	Diabetes Mellitus (DM): Tobacco Non-Use	Clinical Process/Effectiveness	140	80.48	16.53
HF-6	Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	Clinical Process/Effectiveness	133	89.92	9.71
HTN-2	Hypertension (HTN): Controlling High Blood Pressure	Clinical Process/Effectiveness	143	65.91	12.80
IVD-1	Ischemic Vascular Disease (IVD): Complete Lipid Panel and Low Density Lipoprotein (LDL-C) Control	Clinical Process/Effectiveness	136	59.84	12.27
IVD-2	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	Clinical Process/Effectiveness	136	86.68	13.86
Prev-5	Preventive Care and Screening: Breast Cancer Screening for Women Aged 40-69	Clinical Process/Effectiveness	138	67.24	15.16

			TINs with 25 or More Eligible Professionals (at least One of Whom is a Physician)		
PQRS Measure Number and Name		Quality Domain	Number of TINs Reporting	Mean	Standard Deviation
Prev-6	Preventive Care and Screening: Colorectal Cancer Screening	Clinical Process/Effectiveness	138	64.42	17.91
Prev-8	Preventive Care and Screening: Pneumococcal Vaccination for Patients 65 Years and Older	Clinical Process/Effectiveness	140	64.24	22.55
Prev-7	Preventive Care and Screening: Influenza Immunization	Population/Public Health	139	64.28	19.06
Prev-9	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	Population/Public Health	142	61.24	19.89
Prev-10	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	Population/Public Health	143	90.13	16.20
Prev-11	Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	Population/Public Health	140	67.72	24.93
Prev-12	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	Population/Public Health	140	19.91	21.56
Care-1	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	Patient Safety	134	85.87	21.01
Care-2	Falls: Screening for Future Fall Risk	Patient Safety	140	44.85	29.05

\*\*Lower performance rates on this measure indicate better performance.

**Table 4. GPRO Registry Quality Measures. 2013 Performance Means and Standard Deviations for All TINs Electing this Reporting Option in 2013.**

PQRS Measure Number and Name	Quality Domain	TINs with Two or More Eligible Professionals (at least One of Whom is a Physician)		
		Number of TINs Reporting	Mean	Standard Deviation
1** Diabetes Mellitus (DM): Hemoglobin A1c Poor Control	Clinical Process/Effectiveness	100	29.86	18.91
2 Diabetes Mellitus (DM): Low Density Lipoprotein (LDL-C) Control	Clinical Process/Effectiveness	84	47.49	18.55
3 Diabetes Mellitus (DM): High Blood Pressure Control	Clinical Process/Effectiveness	124	68.87	19.33
5 Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	Clinical Process/Effectiveness	21	87.97	14.48
6 Coronary Artery Disease (CAD): Antiplatelet Therapy	Clinical Process/Effectiveness	33	82.07	20.38
7 Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVSD) (LVEF < 40%)	Clinical Process/Effectiveness	18	74.99	29.72
8 Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	Clinical Process/Effectiveness	4	97.39	3.94
9 Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	Clinical Process/Effectiveness	5	21.26	21.67
12 Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation	Clinical Process/Effectiveness	12	91.55	15.02
14 Age-Related Macular Degeneration (AMD): Dilated Macular Examination	Clinical Process/Effectiveness	3	27.04	16.96
18 Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	Clinical Process/Effectiveness	6	61.97	26.77
19 Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	Clinical Process/Effectiveness	5	29.13	16.92
28 Aspirin at Arrival for Acute Myocardial Infarction (AMI)	Clinical Process/Effectiveness	3	92.98	6.68
31 Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	Clinical Process/Effectiveness	7	90.30	6.60
32 Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	Clinical Process/Effectiveness	17	93.84	7.30



PQRS Measure Number and Name	Quality Domain	TINs with Two or More Eligible Professionals (at least One of Whom is a Physician)			
		Number of TINs Reporting	Mean	Standard Deviation	
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge	Clinical Process/Effectiveness	16	90.87	9.57
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	Clinical Process/Effectiveness	1	79.10	-
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	Clinical Process/Effectiveness	19	79.61	14.22
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	Clinical Process/Effectiveness	19	38.83	23.11
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	Clinical Process/Effectiveness	2	6.90	7.39
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	Clinical Process/Effectiveness	7	55.70	14.76
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	Clinical Process/Effectiveness	1	90.70	-
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	Clinical Process/Effectiveness	1	98.84	-
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	Clinical Process/Effectiveness	5	45.71	25.00
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	Clinical Process/Effectiveness	1	100.00	-
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	Clinical Process/Effectiveness	4	70.61	15.75
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	Clinical Process/Effectiveness	0	-	-
53	Asthma: Pharmacologic Therapy for Persistent Asthma—Ambulatory Care Setting	Clinical Process/Effectiveness	4	90.45	13.15
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	Clinical Process/Effectiveness	9	87.51	15.47
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	Clinical Process/Effectiveness	11	83.73	26.84
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	Clinical Process/Effectiveness	5	89.87	7.62

PQRS Measure Number and Name	Quality Domain	TINs with Two or More Eligible Professionals (at least One of Whom is a Physician)			
		Number of TINs Reporting	Mean	Standard Deviation	
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	Clinical Process/Effectiveness	4	90.56	9.44
64	Asthma: Assessment of Asthma Control—Ambulatory Care Setting	Clinical Process/Effectiveness	1	40.63	-
67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	Clinical Process/Effectiveness	1	73.08	-
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	Clinical Process/Effectiveness	4	52.28	36.02
69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates	Clinical Process/Effectiveness	3	82.69	21.91
70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	Clinical Process/Effectiveness	0	-	-
71	Breast Cancer: Hormonal Therapy for Stage IC—IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	Clinical Process/Effectiveness	1	94.61	-
72	Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients	Clinical Process/Effectiveness	3	96.02	4.65
83	Hepatitis C: Testing for Chronic Hepatitis C—Confirmation of Hepatitis C Viremia	Clinical Process/Effectiveness	0	-	-
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	Clinical Process/Effectiveness	1	100.00	-
85	Hepatitis C: Hepatitis C Virus (HCV) Genotype Testing Prior to Treatment	Clinical Process/Effectiveness	3	66.28	26.39
86	Hepatitis C: Antiviral Treatment Prescribed	Clinical Process/Effectiveness	1	93.10	-
87	Hepatitis C: Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	Clinical Process/Effectiveness	0	-	-
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	Clinical Process/Effectiveness	5	56.22	26.03
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	Clinical Process/Effectiveness	0	-	-
91	Acute Otitis Externa (AOE): Topical Therapy	Clinical Process/Effectiveness	8	92.03	9.07
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	Clinical Process/Effectiveness	11	98.13	6.21

PQRS Measure Number and Name	Quality Domain	TINs with Two or More Eligible Professionals (at least One of Whom is a Physician)			
		Number of TINs Reporting	Mean	Standard Deviation	
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	Clinical Process/Effectiveness	12	99.24	2.62
104	Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients	Clinical Process/Effectiveness	1	100.00	-
106	Adult Major Depressive Disorder (MDD): Comprehensive Depression Evaluation: Diagnosis and Severity	Clinical Process/Effectiveness	3	37.10	35.25
107	Adult Major Depressive Disorder (MDD): Suicide Risk Assessment	Clinical Process/Effectiveness	5	39.36	41.31
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	Clinical Process/Effectiveness	5	49.87	32.06
111	Preventive Care and Screening: Pneumococcal Vaccination for Patients 65 Years and Older	Clinical Process/Effectiveness	59	41.57	25.54
112	Preventive Care and Screening: Breast Cancer Screening for Women Aged 40-69	Clinical Process/Effectiveness	48	44.80	21.29
113	Preventive Care and Screening: Colorectal Cancer Screening	Clinical Process/Effectiveness	49	41.41	24.25
117	Diabetes Mellitus (DM): Dilated Eye Exam	Clinical Process/Effectiveness	13	59.09	39.66
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy—Diabetes or Left Ventricular Systolic Dysfunction (LVSD) (LVEF < 40%)	Clinical Process/Effectiveness	30	69.78	22.92
119	Diabetes Mellitus (DM): Medical Attention for Nephropathy	Clinical Process/Effectiveness	24	69.79	17.77
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	Clinical Process/Effectiveness	11	61.49	18.66
122	Adult Kidney Disease: Blood Pressure Management	Clinical Process/Effectiveness	8	47.85	6.71
123**	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA)—Hemoglobin Level > 12.0 g/dL	Clinical Process/Effectiveness	0	-	-
126	Diabetes Mellitus (DM): Diabetic Foot and Ankle Care, Peripheral Neuropathy—Neurological Evaluation	Clinical Process/Effectiveness	6	16.88	19.47
127	Diabetes Mellitus (DM): Diabetic Foot and Ankle Care, Ulcer Prevention—Evaluation of Footwear	Clinical Process/Effectiveness	0	-	-

			TINs with Two or More Eligible Professionals (at least One of Whom is a Physician)		
PQRS Measure Number and Name		Quality Domain	Number of TINs Reporting	Mean	Standard Deviation
137	Melanoma: Continuity of Care—Recall System	Clinical Process/Effectiveness	7	90.77	17.20
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	Clinical Process/Effectiveness	5	30.57	10.56
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	Clinical Process/Effectiveness	2	58.45	1.20
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage	Clinical Process/Effectiveness	2	94.99	7.09
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis	Clinical Process/Effectiveness	0	-	-
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy	Clinical Process/Effectiveness	1	98.67	-
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy	Clinical Process/Effectiveness	1	100.00	-
163	Diabetes Mellitus (DM): Foot Exam	Clinical Process/Effectiveness	8	34.80	30.80
164**	Coronary Artery Bypass Graft (CABG): Prolonged Intubation	Clinical Process/Effectiveness	0	-	-
165**	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate	Clinical Process/Effectiveness	0	-	-
166**	Coronary Artery Bypass Graft (CABG): Stroke	Clinical Process/Effectiveness	0	-	-
167**	Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure	Clinical Process/Effectiveness	0	-	-
168**	Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration	Clinical Process/Effectiveness	0	-	-
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge	Clinical Process/Effectiveness	0	-	-
170	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge	Clinical Process/Effectiveness	0	-	-
171	Coronary Artery Bypass Graft (CABG): Anti-Lipid Treatment at Discharge	Clinical Process/Effectiveness	0	-	-
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	Clinical Process/Effectiveness	0	-	-
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	Clinical Process/Effectiveness	0	-	-
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	Clinical Process/Effectiveness	0	-	-

PQRS Measure Number and Name	Quality Domain	TINs with Two or More Eligible Professionals (at least One of Whom is a Physician)			
		Number of TINs Reporting	Mean	Standard Deviation	
178	Rheumatoid Arthritis (RA): Functional Status Assessment	Clinical Process/Effectiveness	1	12.50	-
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	Clinical Process/Effectiveness	1	12.50	-
187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy	Clinical Process/Effectiveness	0	-	-
191	Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery	Clinical Process/Effectiveness	0	-	-
194	Oncology: Cancer Stage Documented	Clinical Process/Effectiveness	2	55.32	63.19
195	Radiology: Stenosis Measurement in Carotid Imaging Reports	Clinical Process/Effectiveness	7	88.27	11.59
197	Coronary Artery Disease (CAD): Lipid Control	Clinical Process/Effectiveness	19	37.06	16.43
198	Heart Failure (HF): Left Ventricular Ejection Fraction (LVEF) Assessment	Clinical Process/Effectiveness	2	22.61	29.85
201	Ischemic Vascular Disease (IVD): Blood Pressure Management	Clinical Process/Effectiveness	30	71.65	24.55
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	Clinical Process/Effectiveness	47	72.76	13.70
205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea	Clinical Process/Effectiveness	0	-	-
208	HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis	Clinical Process/Effectiveness	0	-	-
209	Functional Communication Measure—Spoken Language Comprehension for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	Clinical Process/Effectiveness	0	-	-
210	Functional Communication Measure—Attention for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	Clinical Process/Effectiveness	0	-	-
211	Functional Communication Measure—Memory for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	Clinical Process/Effectiveness	0	-	-
212	Functional Communication Measure—Motor Speech for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	Clinical Process/Effectiveness	0	-	-
213	Functional Communication Measure—Reading for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	Clinical Process/Effectiveness	0	-	-

PQRS Measure Number and Name	Quality Domain	TINs with Two or More Eligible Professionals (at least One of Whom is a Physician)			
		Number of TINs Reporting	Mean	Standard Deviation	
214	Functional Communication Measure—Spoken Language Expression for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	Clinical Process/Effectiveness	0	-	-
215	Functional Communication Measure—Writing for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	Clinical Process/Effectiveness	0	-	-
216	Functional Communication Measure—Swallowing for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	Clinical Process/Effectiveness	0	-	-
228	Heart Failure (HF): Left Ventricular Function (LVF) Testing	Clinical Process/Effectiveness	1	16.92	-
231	Asthma: Tobacco Use: Screening—Ambulatory Care Setting	Clinical Process/Effectiveness	2	57.43	59.11
232	Asthma: Tobacco Use: Intervention—Ambulatory Care Setting	Clinical Process/Effectiveness	1	9.68	-
233	Thoracic Surgery: Recording of Performance Status Prior to Lung or Esophageal Cancer Resection	Clinical Process/Effectiveness	0	-	-
236	Hypertension (HTN): Controlling High Blood Pressure	Clinical Process/Effectiveness	75	68.02	22.26
241	Ischemic Vascular Disease (IVD): Complete Lipid Panel and Low Density Lipoprotein (LDL-C) Control	Clinical Process/Effectiveness	14	38.85	17.68
242	Coronary Artery Disease (CAD): Symptom Management	Clinical Process/Effectiveness	0	-	-
243	Cardiac Rehabilitation Patient Referral from an Outpatient Setting	Clinical Process/Effectiveness	0	-	-
244	Hypertension (HTN): Blood Pressure Management	Clinical Process/Effectiveness	2	59.23	7.05
245	Chronic Wound Care: Use of Wound Surface Culture Technique in Patients with Chronic Skin Ulcers (Overuse Measure)	Clinical Process/Effectiveness	0	-	-
246	Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers (Overuse Measure)	Clinical Process/Effectiveness	1	100.00	-
247	Substance Use Disorders: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence	Clinical Process/Effectiveness	1	100.00	-
248	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence	Clinical Process/Effectiveness	1	10.71	-

PQRS Measure Number and Name	Quality Domain	TINs with Two or More Eligible Professionals (at least One of Whom is a Physician)			
		Number of TINs Reporting	Mean	Standard Deviation	
249	Barrett's Esophagus	Clinical Process/Effectiveness	5	100.00	0.00
250	Radical Prostatectomy Pathology Reporting	Clinical Process/Effectiveness	6	100.00	0.00
251	Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients	Clinical Process/Effectiveness	9	100.00	0.00
252	Anticoagulation for Acute Pulmonary Embolus Patients	Clinical Process/Effectiveness	0	-	-
254	Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain	Clinical Process/Effectiveness	0	-	-
255	Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure	Clinical Process/Effectiveness	0	-	-
257	Statin Therapy at Discharge after Lower Extremity Bypass (LEB)	Clinical Process/Effectiveness	0	-	-
263	Preoperative Diagnosis of Breast Cancer	Clinical Process/Effectiveness	2	78.75	30.05
264	Sentinel Lymph Node Biopsy for Invasive Breast Cancer	Clinical Process/Effectiveness	1	100.00	-
266	Epilepsy: Seizure Type(s) and Current Seizure Frequency(ies)	Clinical Process/Effectiveness	1	57.95	-
267	Epilepsy: Documentation of Etiology of Epilepsy or Epilepsy Syndrome	Clinical Process/Effectiveness	1	61.36	-
268	Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy	Clinical Process/Effectiveness	0	-	-
303	Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery	Clinical Process/Effectiveness	0	-	-
325	Adult Major Depressive Disorder (MDD): Coordination of Care of Patients with Specific Comorbid Conditions	Clinical Process/Effectiveness	0	-	-
327	Pediatric Kidney Disease: Adequacy of Volume Management	Clinical Process/Effectiveness	0	-	-
328**	Pediatric Kidney Disease: End Stage Renal Disease (ESRD) Patients Receiving Dialysis: Hemoglobin Level < 10 g/dL	Clinical Process/Effectiveness	0	-	-
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	Patient and Family Engagement	1	88.89	-
109	Osteoarthritis (OA): Function and Pain Assessment	Patient and Family Engagement	2	18.81	13.88

			TINs with Two or More Eligible Professionals (at least One of Whom is a Physician)		
PQRS Measure Number and Name		Quality Domain	Number of TINs Reporting	Mean	Standard Deviation
143	Oncology: Medical and Radiation—Pain Intensity Quantified	Patient and Family Engagement	0	-	-
144	Oncology: Medical and Radiation—Plan of Care for Pain	Patient and Family Engagement	0	-	-
304	Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery	Patient and Family Engagement	0	-	-
110	Preventive Care and Screening: Influenza Immunization	Population/Public Health	64	39.13	19.99
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	Population/Public Health	62	43.40	17.76
131	Pain Assessment and Follow-Up	Population/Public Health	1	93.15	-
134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	Population/Public Health	0	-	-
173	Preventive Care and Screening: Unhealthy Alcohol Use—Screening	Population/Public Health	17	59.97	31.68
183	Hepatitis C: Hepatitis A Vaccination in Patients with Hepatitis C Virus (HCV)	Population/Public Health	3	22.89	4.37
184	Hepatitis C: Hepatitis B Vaccination in Patients with Hepatitis C Virus (HCV)	Population/Public Health	3	21.90	6.77
226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	Population/Public Health	87	73.26	24.30
317	Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	Population/Public Health	29	47.29	23.43
20	Perioperative Care: Timing of Prophylactic Parenteral Antibiotic—Ordering Physician	Patient Safety	15	88.16	21.19
21	Perioperative Care: Selection of Prophylactic Antibiotic—First OR Second Generation Cephalosporin	Patient Safety	11	68.75	31.02
22	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Non-Cardiac Procedures)	Patient Safety	12	85.42	14.94
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	Patient Safety	11	87.64	22.44
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	Patient Safety	1	100.00	-
45	Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	Patient Safety	2	94.78	7.39



PQRS Measure Number and Name	Quality Domain	TINs with Two or More Eligible Professionals (at least One of Whom is a Physician)			
		Number of TINs Reporting	Mean	Standard Deviation	
46	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	Patient Safety	20	86.35	11.98
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	Patient Safety	8	98.09	1.36
130	Documentation of Current Medications in the Medical Record	Patient Safety	49	66.79	30.19
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	Patient Safety	5	59.16	50.67
154	Falls: Risk Assessment	Patient Safety	1	84.27	-
156	Oncology: Radiation Dose Limits to Normal Tissues	Patient Safety	1	33.33	-
157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection	Patient Safety	0	-	-
181	Elder Maltreatment Screen and Follow-Up Plan	Patient Safety	0	-	-
192**	Cataracts: Complications Within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures	Patient Safety	0	-	-
193	Perioperative Temperature Management	Patient Safety	0	-	-
234	Thoracic Surgery: Pulmonary Function Tests Before Major Anatomic Lung Resection (Pneumonectomy, Lobectomy or Formal Segmentectomy)	Patient Safety	0	-	-
262	Image Confirmation of Successful Excision of Image-Localized Breast Lesion	Patient Safety	1	100.00	-
326	Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy	Patient Safety	1	75.00	-
24	Osteoporosis: Communication with the Physician Managing Ongoing Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	Care Coordination	2	18.49	22.48
47	Advance Care Plan	Care Coordination	17	52.60	32.77
81	Adult Kidney Disease: Hemodialysis Adequacy: Solute	Care Coordination	0	-	-
82	Adult Kidney Disease: Peritoneal Dialysis Adequacy: Solute	Care Coordination	0	-	-

			TINs with Two or More Eligible Professionals (at least One of Whom is a Physician)		
PQRS Measure Number and Name		Quality Domain	Number of TINs Reporting	Mean	Standard Deviation
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy—Avoidance of Inappropriate Use	Care Coordination	8	95.51	8.27
138	Melanoma: Coordination of Care	Care Coordination	7	93.06	13.31
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	Care Coordination	1	90.31	-
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	Care Coordination	9	69.76	21.37
155	Falls: Plan of Care	Care Coordination	3	75.21	42.94
180	Rheumatoid Arthritis (RA): Glucocorticoid Management	Care Coordination	0	-	-
182	Functional Outcome Assessment	Care Coordination	3	92.93	6.65
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use	Care Coordination	2	92.20	1.82
188	Referral for Otolgic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	Care Coordination	0	-	-
217	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Knee Impairments	Care Coordination	0	-	-
218	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Hip Impairments	Care Coordination	0	-	-
219	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lower Leg, Foot or Ankle Impairments	Care Coordination	0	-	-
220	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lumbar Spine Impairments	Care Coordination	0	-	-
221	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Shoulder Impairments	Care Coordination	0	-	-
222	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Wrist or Hand Impairments	Care Coordination	0	-	-

PQRS Measure Number and Name	Quality Domain	TINs with Two or More Eligible Professionals (at least One of Whom is a Physician)			
		Number of TINs Reporting	Mean	Standard Deviation	
223	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs or Other General Orthopedic Impairments	Care Coordination	0	-	-
225	Radiology: Reminder System for Mammograms	Care Coordination	10	83.44	35.84
256	Surveillance After Endovascular Abdominal Aneurysm Repair Care Coordination (EVAR)	Care Coordination	1	8.33	-
258	Rate of Open Repair of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7)	Care Coordination	0	-	-
259	Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2)	Care Coordination	1	60.00	-
260	Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients without Major Complications (Discharged to Home by Post-Operative Day #2)	Care Coordination	0	-	-
261	Referral to Otologic Evaluation for Patients with Acute or Chronic Dizziness	Care Coordination	0	-	-
265	Biopsy Follow-Up	Care Coordination	2	74.53	34.69
320	Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients	Care Coordination	1	24.03	-
321	Participation by a Hospital, Physician or Other Clinician in a Systematic Clinical Database Registry that Includes Consensus Endorsed Quality	Care Coordination	0	-	-
65	Appropriate Treatment for Children with Upper Respiratory Infection (URI)	Efficient Use of Health Care Resources	0	-	-
66	Appropriate Testing for Children with Pharyngitis	Efficient Use of Health Care Resources	0	-	-
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	Efficient Use of Health Care Resources	1	100.00	-
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	Efficient Use of Health Care Resources	0	-	-

PQRS Measure Number and Name	Quality Domain	TINs with Two or More Eligible Professionals (at least One of Whom is a Physician)		
		Number of TINs Reporting	Mean	Standard Deviation
146** Radiology: Inappropriate Use of 'Probably Benign' Assessment Category in Mammography Screening	Efficient Use of Health Care Resources	7	0.66	0.92
224 Melanoma: Overutilization of Imaging Studies in Melanoma	Efficient Use of Health Care Resources	7	94.44	14.70
322** Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients	Efficient Use of Health Care Resources	0	-	-
323** Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI)	Efficient Use of Health Care Resources	0	-	-
324** Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low Risk Patients	Efficient Use of Health Care Resources	0	-	-

\*\*Lower performance rates on this measure indicate better performance.

**Table 5. Payment-Standardized and Risk-Adjusted Per Capita Costs for All Beneficiaries and for Beneficiaries with Specific Conditions. 2013 Performance Means and Standard Deviations for TINs Receiving a 2013 QRUR, by TIN Size.**

Performance Measure	TINs with 1-99 Eligible Professionals (at least One of Whom Is a Physician)			TINs with 100 or More Eligible Professionals (at least One of Whom Is a Physician)		
	Number of TINs Reporting	Mean (\$)	Standard Deviation (\$)	Number of TINs Reporting	Mean (\$)	Standard Deviation (\$)
All Beneficiaries	139,337	\$8,454	\$7,924	912	\$10,235	\$4,203
Beneficiaries with Specific Conditions	-	-	-	-	-	-
Diabetes	101,467	\$13,667	\$13,121	881	\$15,030	\$7,087
COPD	72,702	\$23,656	\$18,131	856	\$24,543	\$8,984
Coronary Artery Disease	102,556	\$15,162	\$13,014	874	\$17,719	\$7,990
Heart Failure	81,685	\$23,026	\$17,753	868	\$25,849	\$9,104

**Table 6. Performance on Payment-Standardized, Risk-Adjusted and Specialty-Adjusted Cost Measures for the 2016 Value-Based Payment Modifier. 2013 Performance Means and Standard Deviations for TINs Receiving a 2013 QRUR, by TIN Size.**

Performance Measure	TINs with 1-99 Eligible Professionals (at least One of Whom Is a Physician)			TINs with 100 or More Eligible Professionals (at least One of Whom Is a Physician)		
	Number of TINs Reporting	Mean (\$)	Standard Deviation (\$)	Number of TINs Reporting	Mean (\$)	Standard Deviation (\$)
All Beneficiaries	139,337	\$9,242	\$8,460	912	\$10,838	\$4,397
Spending per Hospital Patient with Medicare (or Medicare Spending per Beneficiary)	62,018	\$20,074	\$5,745	944	\$19,614	\$2,280
Beneficiaries with Specific Conditions	-	-	-	-	-	-
Diabetes	101,467	\$14,697	\$13,947	881	\$15,911	\$7,386
COPD	72,702	\$24,272	\$18,495	856	\$24,796	\$8,934
Coronary Artery Disease	102,556	\$15,912	\$13,506	874	\$18,239	\$8,016
Heart Failure	81,685	\$24,013	\$18,419	868	\$26,635	\$9,171

**Table 7. 2013 Aggregate Group-Level Performance on PQRS Quality Measures for the 2016 Value-Based Payment Modifier. 2013 Performance Means and Standard Deviations for TINs Receiving a 2013 QRUR, Among Incentive-Eligible Individual Eligible Professionals.**

			TINs with at least One Eligible Professional Who Participated in PQRS as an Individual and Were Incentive-Eligible under the TIN in 2013		
PQRS Measure Number and Name	Quality Domain	Number of TINs Reporting	Mean	Standard Deviation	
1**	Diabetes Mellitus (DM): Hemoglobin A1c Poor Control	Clinical Process/Effectiveness	6,612	13.69	18.72
2	Diabetes Mellitus (DM): Low Density Lipoprotein (LDL-C) Control	Clinical Process/Effectiveness	5,494	62.15	23.85
3	Diabetes Mellitus (DM): High Blood Pressure Control	Clinical Process/Effectiveness	6,719	75.53	18.45
5	Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	Clinical Process/Effectiveness	405	84.64	22.39
6	Coronary Artery Disease (CAD): Antiplatelet Therapy	Clinical Process/Effectiveness	3,045	84.10	22.20
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVSD) (LVEF < 40%)	Clinical Process/Effectiveness	812	76.54	21.09
8	Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	Clinical Process/Effectiveness	326	86.68	23.19
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	Clinical Process/Effectiveness	704	78.14	32.26
12	Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation	Clinical Process/Effectiveness	5,207	97.68	8.31
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	Clinical Process/Effectiveness	5,205	96.60	13.47
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	Clinical Process/Effectiveness	4,275	97.96	9.69
19	Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	Clinical Process/Effectiveness	2,727	95.57	16.09
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	Clinical Process/Effectiveness	1,375	89.84	11.65

TINs with at least One Eligible Professional Who Participated in PQRS as an Individual and Were Incentive-Eligible under the TIN in 2013

PQRS Measure Number and Name		Quality Domain	Number of TINs Reporting	Mean	Standard Deviation
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	Clinical Process/Effectiveness	547	92.88	14.34
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	Clinical Process/Effectiveness	287	92.67	13.76
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge	Clinical Process/Effectiveness	20	92.50	21.34
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	Clinical Process/Effectiveness	351	94.26	14.70
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	Clinical Process/Effectiveness	287	91.16	14.43
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	Clinical Process/Effectiveness	3,842	61.88	37.06
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	Clinical Process/Effectiveness	168	88.06	26.05
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	Clinical Process/Effectiveness	1,092	87.50	23.13
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	Clinical Process/Effectiveness	205	99.11	2.93
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	Clinical Process/Effectiveness	183	96.42	7.70
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	Clinical Process/Effectiveness	2,752	84.75	30.42
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	Clinical Process/Effectiveness	619	97.31	9.21
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	Clinical Process/Effectiveness	929	92.99	18.38
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	Clinical Process/Effectiveness	480	97.81	9.73



			TINs with at least One Eligible Professional Who Participated in PQRS as an Individual and Were Incentive-Eligible under the TIN in 2013		
PQRS Measure Number and Name		Quality Domain	Number of TINs Reporting	Mean	Standard Deviation
53	Asthma: Pharmacologic Therapy for Persistent Asthma—Ambulatory Care Setting	Clinical Process/Effectiveness	262	98.25	9.06
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	Clinical Process/Effectiveness	1,656	95.65	8.78
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	Clinical Process/Effectiveness	1,543	96.88	6.39
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	Clinical Process/Effectiveness	1,966	97.42	7.98
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	Clinical Process/Effectiveness	1,680	95.61	8.42
64	Asthma: Assessment of Asthma Control—Ambulatory Care Setting	Clinical Process/Effectiveness	146	96.41	12.10
67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	Clinical Process/Effectiveness	244	97.73	7.23
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	Clinical Process/Effectiveness	194	95.85	13.85
69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates	Clinical Process/Effectiveness	316	93.47	13.04
70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	Clinical Process/Effectiveness	308	98.28	5.11
71	Breast Cancer: Hormonal Therapy for Stage IC—IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	Clinical Process/Effectiveness	533	96.89	9.33
72	Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients	Clinical Process/Effectiveness	287	98.36	6.93
83	Hepatitis C: Testing for Chronic Hepatitis C—Confirmation of Hepatitis C Viremia	Clinical Process/Effectiveness	0	-	-
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	Clinical Process/Effectiveness	72	97.79	8.44
85	Hepatitis C: Hepatitis C Virus (HCV) Genotype Testing Prior to Treatment	Clinical Process/Effectiveness	69	98.12	6.10

TINs with at least One Eligible Professional Who Participated in PQRS as an Individual and Were Incentive-Eligible under the TIN in 2013

PQRS Measure Number and Name		Quality Domain	Number of TINs Reporting	Mean	Standard Deviation
86	Hepatitis C: Antiviral Treatment Prescribed	Clinical Process/Effectiveness	90	83.44	27.43
87	Hepatitis C: Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	Clinical Process/Effectiveness	0	-	-
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	Clinical Process/Effectiveness	253	94.01	16.21
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	Clinical Process/Effectiveness	0	-	-
91	Acute Otitis Externa (AOE): Topical Therapy	Clinical Process/Effectiveness	809	96.25	10.87
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	Clinical Process/Effectiveness	794	97.54	9.68
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	Clinical Process/Effectiveness	727	98.26	6.82
104	Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients	Clinical Process/Effectiveness	158	93.93	15.70
106	Adult Major Depressive Disorder (MDD): Comprehensive Depression Evaluation: Diagnosis and Severity	Clinical Process/Effectiveness	98	86.51	28.75
107	Adult Major Depressive Disorder (MDD): Suicide Risk Assessment	Clinical Process/Effectiveness	196	89.61	23.29
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	Clinical Process/Effectiveness	913	96.69	10.94
111	Preventive Care and Screening: Pneumococcal Vaccination for Patients 65 Years and Older	Clinical Process/Effectiveness	5,636	63.93	36.36
112	Preventive Care and Screening: Breast Cancer Screening for Women Aged 40-69	Clinical Process/Effectiveness	4,871	66.91	33.70
113	Preventive Care and Screening: Colorectal Cancer Screening	Clinical Process/Effectiveness	5,225	64.93	35.69
117	Diabetes Mellitus (DM): Dilated Eye Exam	Clinical Process/Effectiveness	8,229	86.55	25.65

TINs with at least One Eligible Professional Who Participated in PQRS as an Individual and Were Incentive-Eligible under the TIN in 2013

PQRS Measure Number and Name		Quality Domain	Number of TINs Reporting	Mean	Standard Deviation
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy—Diabetes or Left Ventricular Systolic Dysfunction (LVSD) (LVEF < 40%)	Clinical Process/Effectiveness	236	73.06	27.58
119	Diabetes Mellitus (DM): Medical Attention for Nephropathy	Clinical Process/Effectiveness	5,109	88.65	17.61
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	Clinical Process/Effectiveness	840	79.65	27.57
122	Adult Kidney Disease: Blood Pressure Management	Clinical Process/Effectiveness	539	89.06	20.14
123**	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA)—Hemoglobin Level > 12.0 g/dL	Clinical Process/Effectiveness	454	8.27	16.70
126	Diabetes Mellitus (DM): Diabetic Foot and Ankle Care, Peripheral Neuropathy—Neurological Evaluation	Clinical Process/Effectiveness	1,985	93.95	18.30
127	Diabetes Mellitus (DM): Diabetic Foot and Ankle Care, Ulcer Prevention—Evaluation of Footwear	Clinical Process/Effectiveness	0	-	-
137	Melanoma: Continuity of Care—Recall System	Clinical Process/Effectiveness	1,547	97.58	10.89
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	Clinical Process/Effectiveness	4,178	95.26	15.44
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	Clinical Process/Effectiveness	962	86.98	21.31
149	Back Pain: Physical Exam	Clinical Process/Effectiveness	0	-	-
150	Back Pain: Advice for Normal Activities	Clinical Process/Effectiveness	0	-	-
151	Back Pain: Advice Against Bed Rest	Clinical Process/Effectiveness	0	-	-
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage	Clinical Process/Effectiveness	44	97.77	5.28
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis	Clinical Process/Effectiveness	0	-	-
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy	Clinical Process/Effectiveness	40	97.97	9.29

TINs with at least One Eligible Professional Who Participated in PQRS as an Individual and Were Incentive-Eligible under the TIN in 2013

PQRS Measure Number and Name		Quality Domain	Number of TINs Reporting	Mean	Standard Deviation
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy	Clinical Process/Effectiveness	42	99.32	2.31
163	Diabetes Mellitus (DM): Foot Exam	Clinical Process/Effectiveness	4,768	83.71	28.57
164**	Coronary Artery Bypass Graft (CABG): Prolonged Intubation	Clinical Process/Effectiveness	0	-	-
165**	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate	Clinical Process/Effectiveness	0	-	-
166**	Coronary Artery Bypass Graft (CABG): Stroke	Clinical Process/Effectiveness	0	-	-
167**	Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure	Clinical Process/Effectiveness	0	-	-
168**	Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration	Clinical Process/Effectiveness	0	-	-
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge	Clinical Process/Effectiveness	0	-	-
170	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge	Clinical Process/Effectiveness	0	-	-
171	Coronary Artery Bypass Graft (CABG): Anti-Lipid Treatment at Discharge	Clinical Process/Effectiveness	0	-	-
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	Clinical Process/Effectiveness	78	95.36	12.57
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	Clinical Process/Effectiveness	430	95.57	14.19
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	Clinical Process/Effectiveness	593	95.80	14.98
178	Rheumatoid Arthritis (RA): Functional Status Assessment	Clinical Process/Effectiveness	679	92.87	20.25
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	Clinical Process/Effectiveness	521	90.37	23.26
187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy	Clinical Process/Effectiveness	6	100.00	0.00
191	Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery	Clinical Process/Effectiveness	0	-	-

TINs with at least One Eligible Professional Who Participated in PQRS as an Individual and Were Incentive-Eligible under the TIN in 2013

PQRS Measure Number and Name		Quality Domain	Number of TINs Reporting	Mean	Standard Deviation
194	Oncology: Cancer Stage Documented	Clinical Process/Effectiveness	783	94.82	14.35
195	Radiology: Stenosis Measurement in Carotid Imaging Reports	Clinical Process/Effectiveness	1,306	79.38	25.41
197	Coronary Artery Disease (CAD): Lipid Control	Clinical Process/Effectiveness	845	58.51	34.48
198	Heart Failure (HF): Left Ventricular Ejection Fraction (LVEF) Assessment	Clinical Process/Effectiveness	185	73.14	34.23
200	Heart Failure (HF): Warfarin Therapy for Patients with Atrial Fibrillation	Clinical Process/Effectiveness	0	-	-
201	Ischemic Vascular Disease (IVD): Blood Pressure Management	Clinical Process/Effectiveness	2,317	80.66	18.54
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	Clinical Process/Effectiveness	2,548	77.70	26.52
205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea	Clinical Process/Effectiveness	0	-	-
208	HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis	Clinical Process/Effectiveness	0	-	-
209	Functional Communication Measure—Spoken Language Comprehension for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	Clinical Process/Effectiveness	0	-	-
210	Functional Communication Measure—Attention for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	Clinical Process/Effectiveness	0	-	-
211	Functional Communication Measure—Memory for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	Clinical Process/Effectiveness	0	-	-
212	Functional Communication Measure—Motor Speech for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	Clinical Process/Effectiveness	0	-	-
213	Functional Communication Measure—Reading for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	Clinical Process/Effectiveness	0	-	-

TINs with at least One Eligible Professional Who Participated in PQRS as an Individual and Were Incentive-Eligible under the TIN in 2013

PQRS Measure Number and Name		Quality Domain	Number of TINS Reporting	Mean	Standard Deviation
214	Functional Communication Measure—Spoken Language Expression for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	Clinical Process/Effectiveness	0	-	-
215	Functional Communication Measure—Writing for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	Clinical Process/Effectiveness	0	-	-
216	Functional Communication Measure—Swallowing for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	Clinical Process/Effectiveness	0	-	-
228	Heart Failure (HF): Left Ventricular Function (LVF) Testing	Clinical Process/Effectiveness	50	84.75	18.67
231	Asthma: Tobacco Use: Screening—Ambulatory Care Setting	Clinical Process/Effectiveness	270	97.75	9.50
232	Asthma: Tobacco Use: Intervention—Ambulatory Care Setting	Clinical Process/Effectiveness	50	97.76	9.03
233	Thoracic Surgery: Recording of Performance Status Prior to Lung or Esophageal Cancer Resection	Clinical Process/Effectiveness	0	-	-
236	Hypertension (HTN): Controlling High Blood Pressure	Clinical Process/Effectiveness	3,897	74.93	20.90
237	Hypertension (HTN): Blood Pressure Measurement	Clinical Process/Effectiveness	0	-	-
241	Ischemic Vascular Disease (IVD): Complete Lipid Panel and Low Density Lipoprotein (LDL-C) Control	Clinical Process/Effectiveness	1,338	64.13	31.56
242	Coronary Artery Disease (CAD): Symptom Management	Clinical Process/Effectiveness	331	91.08	20.75
243	Cardiac Rehabilitation Patient Referral from an Outpatient Setting	Clinical Process/Effectiveness	0	-	-
244	Hypertension (HTN): Blood Pressure Management	Clinical Process/Effectiveness	63	74.25	19.24
245	Chronic Wound Care: Use of Wound Surface Culture Technique in Patients with Chronic Skin Ulcers (Overuse Measure)	Clinical Process/Effectiveness	141	95.44	12.61
246	Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers (Overuse Measure)	Clinical Process/Effectiveness	169	92.97	17.71

TINs with at least One Eligible Professional Who Participated in PQRS as an Individual and Were Incentive-Eligible under the TIN in 2013

PQRS Measure Number and Name		Quality Domain	Number of TINS Reporting	Mean	Standard Deviation
247	Substance Use Disorders: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence	Clinical Process/Effectiveness	60	99.83	1.29
248	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence	Clinical Process/Effectiveness	108	96.15	14.98
249	Barrett's Esophagus	Clinical Process/Effectiveness	730	99.24	5.22
250	Radical Prostatectomy Pathology Reporting	Clinical Process/Effectiveness	469	99.42	3.50
251	Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients	Clinical Process/Effectiveness	477	99.41	4.75
252	Anticoagulation for Acute Pulmonary Embolus Patients	Clinical Process/Effectiveness	0	-	-
254	Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain	Clinical Process/Effectiveness	0	-	-
255	Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure	Clinical Process/Effectiveness	0	-	-
257	Statin Therapy at Discharge after Lower Extremity Bypass (LEB)	Clinical Process/Effectiveness	7	80.98	18.16
263	Preoperative Diagnosis of Breast Cancer	Clinical Process/Effectiveness	143	98.04	9.98
264	Sentinel Lymph Node Biopsy for Invasive Breast Cancer	Clinical Process/Effectiveness	105	94.90	8.86
266	Epilepsy: Seizure Type(s) and Current Seizure Frequency(ies)	Clinical Process/Effectiveness	242	97.81	9.28
267	Epilepsy: Documentation of Etiology of Epilepsy or Epilepsy Syndrome	Clinical Process/Effectiveness	196	96.06	12.79
268	Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy	Clinical Process/Effectiveness	0	-	-
269	Inflammatory Bowel Disease (IBD): Type, Anatomic Location and Activity All Documented	Clinical Process/Effectiveness	0	-	-
270	Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy	Clinical Process/Effectiveness	0	-	-
271	Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Related Iatrogenic Injury—Bone Loss Assessment	Clinical Process/Effectiveness	0	-	-

TINs with at least One Eligible Professional Who Participated in PQRS as an Individual and Were Incentive-Eligible under the TIN in 2013

PQRS Measure Number and Name		Quality Domain	Number of TINS Reporting	Mean	Standard Deviation
272	Inflammatory Bowel Disease (IBD): Preventive Care: Influenza Immunization	Clinical Process/Effectiveness	0	-	-
273	Inflammatory Bowel Disease (IBD): Preventive Care: Pneumococcal Immunization	Clinical Process/Effectiveness	0	-	-
274	Inflammatory Bowel Disease (IBD): Testing for Latent Tuberculosis (TB) Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy	Clinical Process/Effectiveness	0	-	-
275	Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy	Clinical Process/Effectiveness	0	-	-
276	Sleep Apnea: Assessment of Sleep Symptoms	Clinical Process/Effectiveness	0	-	-
277	Sleep Apnea: Severity Assessment at Initial Diagnosis	Clinical Process/Effectiveness	0	-	-
278	Sleep Apnea: Positive Airway Pressure Therapy Prescribed	Clinical Process/Effectiveness	0	-	-
279	Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy	Clinical Process/Effectiveness	0	-	-
281	Dementia: Cognitive Assessment	Clinical Process/Effectiveness	0	-	-
282	Dementia: Functional Status Assessment	Clinical Process/Effectiveness	0	-	-
283	Dementia: Neuropsychiatric Symptom Assessment	Clinical Process/Effectiveness	0	-	-
284	Dementia: Management of Neuropsychiatric Symptoms	Clinical Process/Effectiveness	0	-	-
285	Dementia: Screening for Depressive Symptoms	Clinical Process/Effectiveness	0	-	-
287	Dementia: Counseling Regarding Risks of Driving	Clinical Process/Effectiveness	0	-	-
288	Dementia: Caregiver Education and Support	Clinical Process/Effectiveness	0	-	-
289	Parkinson's Disease: Annual Parkinson's Disease Diagnosis Review	Clinical Process/Effectiveness	0	-	-
290	Parkinson's Disease: Psychiatric Disorders or Disturbances Assessment	Clinical Process/Effectiveness	0	-	-



TINs with at least One Eligible Professional Who Participated in PQRS as an Individual and Were Incentive-Eligible under the TIN in 2013

PQRS Measure Number and Name		Quality Domain	Number of TINS Reporting	Mean	Standard Deviation
291	Parkinson's Disease: Cognitive Impairment or Dysfunction Assessment	Clinical Process/Effectiveness	0	-	-
292	Parkinson's Disease: Querying about Sleep Disturbances	Clinical Process/Effectiveness	0	-	-
293	Parkinson's Disease: Rehabilitative Therapy Options	Clinical Process/Effectiveness	0	-	-
294	Parkinson's Disease: Parkinson's Disease Medical and Surgical Treatment Options Reviewed	Clinical Process/Effectiveness	0	-	-
295	Hypertension (HTN): Appropriate Use of Aspirin or Other Antithrombotic Therapy	Clinical Process/Effectiveness	0	-	-
296	Hypertension (HTN): Complete Lipid Profile	Clinical Process/Effectiveness	0	-	-
297	Hypertension (HTN): Urine Protein Test	Clinical Process/Effectiveness	0	-	-
298	Hypertension (HTN): Annual Serum Creatinine Test	Clinical Process/Effectiveness	0	-	-
299	Hypertension (HTN): Diabetes Mellitus Screening Test	Clinical Process/Effectiveness	0	-	-
300	Hypertension (HTN): Blood Pressure Control	Clinical Process/Effectiveness	0	-	-
301	Hypertension (HTN): Low Density Lipoprotein (LDL-C) Control	Clinical Process/Effectiveness	0	-	-
302	Hypertension (HTN): Dietary and Physical Activity Modifications Appropriately Prescribed	Clinical Process/Effectiveness	0	-	-
303	Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery	Clinical Process/Effectiveness	0	-	-
305	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement	Clinical Process/Effectiveness	0	-	-
309	Cervical Cancer Screening	Clinical Process/Effectiveness	0	-	-
311	Use of Appropriate Medications for Asthma	Clinical Process/Effectiveness	0	-	-
313	Diabetes Mellitus (DM): Hemoglobin A1c Control (< 8%)	Clinical Process/Effectiveness	0	-	-
316	Preventive Care and Screening: Cholesterol—Fasting Low Density Lipoprotein (LDL) Test Performed AND Risk-Stratified Fasting LDL	Clinical Process/Effectiveness	0	-	-

			TINs with at least One Eligible Professional Who Participated in PQRS as an Individual and Were Incentive-Eligible under the TIN in 2013		
PQRS Measure Number and Name		Quality Domain	Number of TINS Reporting	Mean	Standard Deviation
325	Adult Major Depressive Disorder (MDD): Coordination of Care of Patients with Specific Comorbid Conditions	Clinical Process/Effectiveness	0	-	-
327	Pediatric Kidney Disease: Adequacy of Volume Management	Clinical Process/Effectiveness	0	-	-
328**	Pediatric Kidney Disease: End Stage Renal Disease (ESRD) Patients Receiving Dialysis: Hemoglobin Level < 10 g/dL	Clinical Process/Effectiveness	0	-	-
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	Patient and Family Engagement	771	98.14	7.66
109	Osteoarthritis (OA): Function and Pain Assessment	Patient and Family Engagement	627	91.38	19.42
143	Oncology: Medical and Radiation—Pain Intensity Quantified	Patient and Family Engagement	0	-	-
144	Oncology: Medical and Radiation—Plan of Care for Pain	Patient and Family Engagement	0	-	-
304	Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery	Patient and Family Engagement	0	-	-
110	Preventive Care and Screening: Influenza Immunization	Population/Public Health	5,590	67.68	35.19
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	Population/Public Health	8,167	67.26	28.20
131	Pain Assessment and Follow-Up	Population/Public Health	5,386	94.76	16.09
134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	Population/Public Health	802	96.10	13.38
173	Preventive Care and Screening: Unhealthy Alcohol Use—Screening	Population/Public Health	3,428	81.37	34.23
183	Hepatitis C: Hepatitis A Vaccination in Patients with Hepatitis C Virus (HCV)	Population/Public Health	139	80.45	27.30
184	Hepatitis C: Hepatitis B Vaccination in Patients with Hepatitis C Virus (HCV)	Population/Public Health	146	80.60	27.00
226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	Population/Public Health	11,390	87.08	27.38
239	Weight Assessment and Counseling for Children and Adolescents	Population/Public Health	0	-	-

TINs with at least One Eligible Professional Who Participated in PQRS as an Individual and Were Incentive-Eligible under the TIN in 2013

PQRS Measure Number and Name		Quality Domain	Number of TINs Reporting	Mean	Standard Deviation
240	Childhood Immunization Status	Population/Public Health	0	-	-
306	Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)	Population/Public Health	0	-	-
308	Smoking and Tobacco Use Cessation, Medical Assistance: a. Advising Smokers and Tobacco Users to Quit, b. Discussing Smoking and Tobacco Use Cessation Medications, c. Discussing Smoking and Tobacco Use Cessation Strategies	Population/Public Health	0	-	-
310	Chlamydia Screening for Women	Population/Public Health	0	-	-
317	Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	Population/Public Health	2,814	89.17	23.39
20	Perioperative Care: Timing of Prophylactic Parenteral Antibiotic—Ordering Physician	Patient Safety	1,328	97.39	11.22
21	Perioperative Care: Selection of Prophylactic Antibiotic—First OR Second Generation Cephalosporin	Patient Safety	1,272	95.97	14.03
22	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Non-Cardiac Procedures)	Patient Safety	1,119	97.87	10.64
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	Patient Safety	1,210	96.04	15.96
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	Patient Safety	1,707	93.18	15.42
45	Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	Patient Safety	150	99.49	3.61
46	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	Patient Safety	1,224	97.96	8.98
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	Patient Safety	1,669	86.72	24.49
130	Documentation of Current Medications in the Medical Record	Patient Safety	9,700	92.91	18.50
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	Patient Safety	1,322	71.58	32.17

TINs with at least One Eligible Professional Who Participated in PQRS as an Individual and Were Incentive-Eligible under the TIN in 2013

PQRS Measure Number and Name		Quality Domain	Number of TINs Reporting	Mean	Standard Deviation
154	Falls: Risk Assessment	Patient Safety	725	96.09	14.44
156	Oncology: Radiation Dose Limits to Normal Tissues	Patient Safety	134	98.85	6.28
157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection	Patient Safety	13	93.76	18.37
181	Elder Maltreatment Screen and Follow-Up Plan	Patient Safety	0	-	-
192**	Cataracts: Complications Within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures	Patient Safety	0	-	-
193	Perioperative Temperature Management	Patient Safety	1,339	89.13	17.63
234	Thoracic Surgery: Pulmonary Function Tests Before Major Anatomic Lung Resection (Pneumonectomy, Lobectomy or Formal Segmentectomy)	Patient Safety	0	-	-
238**	Drugs to Be Avoided in the Elderly	Patient Safety	0	-	-
262	Image Confirmation of Successful Excision of Image-Localized Breast Lesion	Patient Safety	132	98.04	9.38
286	Dementia: Counseling Regarding Safety Concerns	Patient Safety	0	-	-
307	Prenatal Care: Anti-D Immune Globulin	Patient Safety	0	-	-
326	Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy	Patient Safety	263	97.97	9.37
24	Osteoporosis: Communication with the Physician Managing Ongoing Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	Care Coordination	199	90.20	22.57
47	Advance Care Plan	Care Coordination	1,576	71.22	35.48
81	Adult Kidney Disease: Hemodialysis Adequacy: Solute	Care Coordination	0	-	-
82	Adult Kidney Disease: Peritoneal Dialysis Adequacy: Solute	Care Coordination	0	-	-
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy—Avoidance of Inappropriate Use	Care Coordination	591	94.88	12.20
138	Melanoma: Coordination of Care	Care Coordination	1,459	94.47	15.60

TINs with at least One Eligible Professional Who Participated in PQRS as an Individual and Were Incentive-Eligible under the TIN in 2013

PQRS Measure Number and Name		Quality Domain	Number of TINs Reporting	Mean	Standard Deviation
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	Care Coordination	2,644	98.57	8.46
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	Care Coordination	955	65.97	26.26
155	Falls: Plan of Care	Care Coordination	617	94.02	17.70
180	Rheumatoid Arthritis (RA): Glucocorticoid Management	Care Coordination	0	-	-
182	Functional Outcome Assessment	Care Coordination	4,066	92.02	19.97
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use	Care Coordination	226	96.77	10.41
188	Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	Care Coordination	0	-	-
217	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Knee Impairments	Care Coordination	0	-	-
218	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Hip Impairments	Care Coordination	0	-	-
219	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lower Leg, Foot or Ankle Impairments	Care Coordination	0	-	-
220	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lumbar Spine Impairments	Care Coordination	0	-	-
221	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Shoulder Impairments	Care Coordination	0	-	-
222	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Wrist or Hand Impairments	Care Coordination	0	-	-
223	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs or Other General Orthopedic Impairments	Care Coordination	0	-	-

			TINs with at least One Eligible Professional Who Participated in PQRS as an Individual and Were Incentive-Eligible under the TIN in 2013		
PQRS Measure Number and Name		Quality Domain	Number of TINs Reporting	Mean	Standard Deviation
225	Radiology: Reminder System for Mammograms	Care Coordination	954	84.04	29.58
256	Surveillance after Endovascular Abdominal Aortic Aneurysm Repair (EVAR)	Care Coordination	3	100.00	0.00
258	Rate of Open Repair of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7)	Care Coordination	2	87.50	17.68
259	Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2)	Care Coordination	9	87.14	12.94
260	Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients without Major Complications (Discharged to Home by Post-Operative Day #2)	Care Coordination	12	89.57	10.88
261	Referral to Otologic Evaluation for Patients with Acute or Chronic Dizziness	Care Coordination	0	-	-
265	Biopsy Follow-Up	Care Coordination	430	94.72	16.82
280	Dementia: Staging of Dementia	Care Coordination	0	-	-
320	Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients	Care Coordination	107	85.89	20.52
321	Participation by a Hospital, Physician or Other Clinician in a Systematic Clinical Database Registry that Includes Consensus Endorsed Quality	Care Coordination	965	100.00	0.06
65	Appropriate Treatment for Children with Upper Respiratory Infection (URI)	Efficient Use of Health Care Resources	11	86.58	28.47
66	Appropriate Testing for Children with Pharyngitis	Efficient Use of Health Care Resources	0	-	-
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	Efficient Use of Health Care Resources	146	96.13	11.26
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	Efficient Use of Health Care Resources	86	85.48	25.24

TINs with at least One Eligible Professional Who Participated in PQRS as an Individual and Were Incentive-Eligible under the TIN in 2013

PQRS Measure Number and Name		Quality Domain	Number of TINs Reporting	Mean	Standard Deviation
146**	Radiology: Inappropriate Use of 'Probably Benign' Assessment Category in Mammography Screening	Efficient Use of Health Care Resources	1,146	0.62	4.07
148	Back Pain: Initial Visit	Efficient Use of Health Care Resources	0	-	-
224	Melanoma: Overutilization of Imaging Studies in Melanoma	Efficient Use of Health Care Resources	1,467	99.29	4.76
312	Low Back Pain: Use of Imaging Studies	Efficient Use of Health Care Resources	0	-	-
322**	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients	Efficient Use of Health Care Resources	4	4.23	6.32
323**	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI)	Efficient Use of Health Care Resources	3	8.46	14.57
324**	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low Risk Patients	Efficient Use of Health Care Resources	3	22.80	33.48

\*\*Lower performance rates on this measure indicate better performance.

**Table 8. 2013 Composite Score Means and Standard Deviations Used for the 2013 QRUR and 2015 Value-Based Payment Modifier.**

To determine the value-based payment modifier under the quality tiering approach, each TIN’s composite scores for quality and cost are categorized as high, low, or average. A composite score that is at least one standard deviation above the mean and also statistically significantly different from the mean at the 5 percent level is considered high. A composite score that is at least one standard deviation below the mean and also statistically significantly different from the mean at the 5 percent level is considered low. A composite score that falls within one standard deviation of the mean is considered average.

Composite Score	Mean	Standard Deviation
Quality Composite Score (Nonstandardized)		
Peer Group of 100+ EP TINs for 100+ EP TINs	0.18	0.61
Peer Group of 1+ EP TINs for 1-99 EP TINs	0.17	0.57
Cost Composite Score (Nonstandardized)		
Peer Group of 100+ EP TINs for 100+ EP TINs	0.07	1.98
Peer Group of 1+ EP TINs for 1-99 EP TINs	-0.30	1.53